ENDOTHELION研究会:NAION患者におけるボセンタンの効果 (ENDOTHELION)
非動脈炎性虚血性視神経症患者におけるボセンタンの効果
Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after glaucoma in the population aged over 50 years. The visual prognosis of the condition is unfavorable in the great majority of cases, with significant effects on the visual field and vision. The severity of the unilateral condition is also associated with bilateralization in 15% at 5 years. There is no effective treatment for the acute phase of the disease or to reduce the rate of bilateralization. In this context, it is essential to develop new therapeutic strategies in the acute phase of the disease to reduce the anatomical optic nerve damage.
調査の概要
詳細な説明
The main objective of our study will be to compare the treatment with bosentan to placebo for 8 weeks for recovery anatomical criteria (RFNL in OCT, optic atrophy) and functional (visual acuity, visual field). The primary endpoint will be the improvement of the visual field, a major criterion of the affected visual function in this disease.
The evaluation of bosentan will mainly after 8 weeks of treatment in order to assess the effectiveness of drug treatment in the absence of continuous positive airway pressure (set up after three months if necessary, feasible confounding factor for the evaluation of results ), the period of three months is sufficient to assess the anatomical and functional recovery (disappearance of papilledema).
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Angers、フランス、49100
- University Hospital of Angers
-
Bordeaux、フランス、33000
- University Hospital of Bordeaux
-
Grenoble、フランス、38043
- CHU de Grenoble
-
Grenoble、フランス、38043
- University Hospital of Grenoble Michallon
-
Paris、フランス、75019
- Ophtalmological fondation of Rothschild + Bichat Hospital
-
Saint-Etienne、フランス、42055
- University hospital of Saint-Etienne
-
-
Paris
-
Paris、Paris、フランス
- Centre National d'Ophtalmologie XV-XX
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Non arteritic ischemic optic neuropathy (NAION) with onset < 21 days
- Age ≥ 50 years old
- Signed informed consent form
- Patients affiliated with a national health insurance scheme or beneficiaries of such a scheme
Exclusion Criteria:
- Pregnant women, women in labour or breast-feeding mother
- Patients with other acute or chronic intercurrent ocular pathology interfering with visual acuity or visual field (diabetes, drug-induced or other retinopathy, other optic neuropathy including uni- or contralateral glaucoma and/or intraocular pressure > 30 mmHg, advanced cataract, corneal opacities, amblyopia < 5/10, severe myopia > -6 diopters, retinal disease)
- Simultaneous bilateral NAAION, 1 month apart or less
- Signs that may raise suspicion of other inflammatory neuropathy: arterial NAAION (Horton's disease), pain on eye movement or any signs suggestive of optic neuritis, known diagnosis of multiple sclerosis, history of inflammatory optic neuropathy (homo- or ipsi-lateral). A temporal artery biopsy should be performed if there are symptoms suggestive of Horton's disease, or if there is pale and/or diffuse edema, or obliteration of the associated central retinal artery.
- Patients with systolic blood pressure below 100 mmHg
- Patient with orthostatic hypotension (20 mmHg drop in SBP and/or 10 mmHg drop in DBP when moving to a standing position)
- Neurological history of vascular or tumour-related changes to the visual field or other optic neuropathy
- Systemic inflammatory disease
- Known allergy to bosentan
- Patients with moderate to severe hepatic impairment (Child-Pugh class B or C), biliary cirrhosis (serum levels of liver aminotransferases, aspartate aminotransferases (ASAT) and/or alanine aminotransferases (ALAT), greater than three times the upper limit of normal, bilirubin greater than twice normal)
- Estimated glomerular filtration rate (GFR) < 30 ml/min/1.73 m2
- Patients treated with drugs whose efficacy may be reduced by activation of cytochrome P450, 2C9, 3A4 and 2C19 isoenzymes
- Patients treated with amiodarone
- Patient treated with systemic corticosteroids (background treatment or treatment initiated at the time of NAAION diagnosis)
- Person deprived of liberty by judicial or administrative decision, adult protected by law, hospitalized person
- Ongoing participation in another clinical research study or in the exclusion period of another clinical study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Bosentan
Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks |
treatment by bosentan or placebo is randomized , 125 mg twice a day |
|
プラセボコンパレーター:Placebo
placebo drug , twice a day, during eight weeks |
treatment by bosentan or placebo is randomized |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
mean deviation of automated visual field
時間枠:3 month
|
Humphrey 30-2 SITA-standard |
3 month
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
visual acuity
時間枠:6, 12 and 24 month
|
ETDRS scale |
6, 12 and 24 month
|
|
optic nerve fiber layer thickness
時間枠:3, 6, 12 and 24 month
|
OCT measurement |
3, 6, 12 and 24 month
|
|
mean deviation of automated visual field for healthy eye and NAION eye
時間枠:3, 6, 12 and 24 month
|
Humphrey 30-2 |
3, 6, 12 and 24 month
|
|
inflammatory marker and prepro-endothelin dosing
時間枠:3 month
|
RANTES, MCP-1, TNF-α, INF-γ, IL-6, IL-10 and TGF-β |
3 month
|
|
mean deviation of automated visual field for controlateral eye
時間枠:24 month
|
Humphrey 30-2 sita-standard |
24 month
|
|
VFQ-25 score
時間枠:3 and 12 month
|
VFQ-25 quality of life |
3 and 12 month
|
|
rate of bilateral occurence of NAION
時間枠:at 24 month visit
|
rate of bilateralization |
at 24 month visit
|
協力者と研究者
捜査官
- 主任研究者:Christophe Pr CHIQUET, Prof, MD, PhD、University Hospital, Grenoble
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。